Given the predicted potential and safety of PTK7 as an immunotherapy target, we sought to develop PTK7-specific CAR T-cell therapy for lung cancer and to evaluate its efficacy and safety in in vitro and in vivo preclinical models. This evidence concerns the gene PTK7 and lung cancer.